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Abstract The release of inflammatory mediators following
cortical spreading depression (CSD) is suggested to play a role
in pathophysiology of CSD-related neurological disorders.
Toll-like receptors (TLR) are master regulators of innate im-
mune function and involved in the activation of inflammatory
responses in the brain. TLR3 agonist poly I:C exerts anti-
inflammatory effect and prevents cell injury in the brain.
The aim of the present study was to examine the effect of
systemic administration of poly I:C on the release of cytokines
(TNF-α, IFN-γ, IL-4, TGF-β1, and GM-CSF) in the brain
and spleen, splenic lymphocyte proliferation, expression of
GAD65, GABAAα, GABAAβ as well as Hsp70, and produc-
tion of dark neurons after induction of repetitive CSD in
juvenile rats. Poly I:C significantly attenuated CSD-induced
production of TNF-α and IFN-γ in the brain as well as TNF-α
and IL-4 in the spleen. Poly I:C did not affect enhancement of
splenic lymphocyte proliferation after CSD. Administration of
poly I:C increased expression of GABAAα, GABAAβ as well
as Hsp70 and decreased expression of GAD65 in the entorhi-
nal cortex compared to CSD-treated tissues. In addition, poly
I:C significantly prevented production of CSD-induced dark
neurons. The data indicate neuroprotective and anti-
inflammatory effects of TLR3 activation on CSD-induced
neuroinflammation. Targeting TLR3 may provide a novel
strategy for developing new treatments for CSD-related neu-
rological disorders.
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Introduction
Cortical spreading depression (CSD) is a slowly propagated
wave of profound neuronal and glial depolarization. CSD is
characterized by a high amplitude negative DC shift associat-
ed with a transient reduction of bioelectrical activity, dramatic
failure of brain ion homeostasis, efflux of excitatory amino
acids from nerve cells, increased energy metabolism, and
changes in cerebral blood flow [1, 2]. Occurrence of CSD is
reported in different cerebrovascular diseases (such as intra-
cranial hemorrhage, stroke, and subarachnoid hemorrhage)
and migraine aura is the human equivalent of CSD. In addi-
tion, clinical and experimental studies indicated that CSDmay
have a role in epilepsy, spinal cord disorders, and transient
global amnesia [3, 4].
A series of evidence suggests that the pain of migraine may
be a form of sterile neurogenic inflammation [5]. An increase
in calcitonin gene-related peptide in the jugular vein [6] and
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vasogenic leakage next to small vessels within the brain
during aura phase of migraine attacks [7, 8] as well as the role
of blocking neurogenic inflammation in prevention of mi-
graine attacks [9] indicate the potential involvement of neu-
roinflammation in the pathogenesis of migraine headache.
The neuroinflammatory response in humans, which is charac-
terized in part by activation of innate immune cells, has been
implicated as a fundamental component for the progression of
damage to the brain following ischemic brain attacks [10].
Propagation of CSD has been suggested to produce local
neurogenic inflammation via the activation of macrophages
and mast cells and subsequent release of different types of
inflammatory mediators [11]. Repetitive CSD triggered a
significant rise in different cytokines (after 6 hours to 3 days),
mostly localize in activated microglial cells and in some
instances the surrounding media; suggesting a crucial role of
CSD in ischemia-mediated neuronal injury in the brain [12].
Changes of cytokines by CSD could contribute to the early
exacerbating and later abating of neuronal injury during is-
chemia [13]. Increased cytokine production and microglial
activation by CSD in association with release of other factors,
such as brain-derived neurotrophic factor, may affect brain
bioelectrical activity and play a role in the transformation of
episodic to chronic migraine [12]. Modulation of cerebral
inflammation by manipulation of cytokine production in the
brain is suggested to improve outcome after an ischemic insult
[14]. Cytokines may influence migraine pain by changing the
sensitivity of intracranial meningeal nociceptors [11, 15].
The immunopotentiator polyinosinic:polycytidylic acid
(poly I:C), a mimic of double-stranded viral RNA, is known
to stimulate toll-like receptor 3 (TLR3) and leads to the
activation of antigen presenting cells, such as B cells, dendritic
cells, and macrophages [16, 17]. Poly I:C has been considered
as an excellent adjuvant in different vaccine and immunother-
apy models for improving humoral and cellular immunity
[18–20]. TLR3 is constitutively expressed in astrocytes, oli-
godendrocytes, and neurons and can be upregulated upon
inflammatory stimulation [21]. Activation of TLR3 plays a
key role in the growth of axons and dendrites, dendrite
branching, and proliferation of embryonic neural progenitor
cells [21, 22]. In addition, TLR3-mediated signaling triggers
production of several immunoregulatory mediators and fac-
tors that enhance neuronal survival, promote angiogenesis as
well as remyelination, and prevent gliosis [21, 23, 24]. Poly
I:C pretreatment exerts neuroprotective and anti-inflammatory
effects in simulated cerebral ischemia models through reduc-
tion of pro-inflammatory cytokine production and enhance-
ment of anti-inflammatory cytokine production from the is-
chemic astrocytes [25]. TLR-4 polymorphism has been re-
ported as a genetic risk factor for migraine [26]. The aim of the
present study was to investigate whether systematic adminis-
tration of poly I:C may modulate CSD-induced inflammation
and neuronal injury in juvenile rats.
Materials and Methods
Animals
Young adult male Wistar rats (25–35 days old; 60–90 g) were
housed under constant temperature (20–22 °C) and a 12:12 h
light–dark cycle and during this time food pellets and water
were available ad libitum. All experiments were carried out
according to the protocol approved by the Ethics Committee
of Shefa Neuroscience Center, Tehran, Iran.
Surgical Procedure and Histological Assessment
Animals were anesthetized with intraperitoneal (i.p.) injection
of chloral hydrate 3.5 % (dissolved in normal saline) and the
head of each rat was placed in the stereotaxic frame (Stoelting
Instruments, USA). The scalp was incised and retracted, a
guide cannula was placed in the skull at the following coor-
dinates: anterior–posterior, +1.8 mm anterior to the bregma;
medial–lateral, −3.1 mm lateral to sagittal suture; and dorsal–
ventral, 0.7 mm down from the skull surface [27]. A stylet was
placed into guide cannula to maintain patency. Two silver
electrodes were implanted over the somatosensory cortex
and reference electrodes were placed on the nasal bulb
(Fig. 1). Electrodes and cannula were fixed with dental acrylic
cement. The scalp was sutured and animals were returned to
their cages. Before the beginning of the experimental proce-
dures, rats were kept for 1 week in well-ventilated boxes in an
air-conditioned room to recover from surgery. Then animals
were anesthetized with chloral hydrate and stylet was with-
drawn from the guide cannula and a microneedle was inserted
into the cannula. The injection microneedle was connected to
a 10 μl Hamilton syringe by a polyethylene tube (Harvard
Apparatus, USA).
KCl solution (3 mol/l) was injected in a total volume of
10 μl within 60 s (CSD group; n=8). The injection needle was
retained in the guide cannula for an additional 60 s after
injection to facilitate diffusion of the solution. In sham
injected controls, 10 μl of Ringer solution was injected ac-
cording to the same injection procedure (sham group; n=8).
Four KCl or Ringer- injections were carried out (with an
interval of 1 week). Anesthesia was continued for 60 min after
each injection of KCl or Ringer solution. Recording of
electrocorticographic (ECoG) signals was performed in anes-
thetized rat for 60 min after each injection.
Five weeks after the first application of KCl or Ringer, rats
were decapitated and the brains were removed. Before decap-
itation, the animals were given a deep anesthesia with chloral
hydrate 3.5 % and perfused transcardially with 200 ml of
saline followed by 600 ml of 1 % paraformaldehyde (PFA)
solution. The brains were extracted and kept in 1 % PFA for
10 days and were then processed for histological assessment.
Coronal uniform random sections were cut through the
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ipsilateral site to the hemisphere in which KCl was injected.
Ten pairs of successive sections were selected by random
systemic sampling from each animal and stained by toluidine
blue. Slides were studied under a light microscope (BX51,
Olympus, Japan) linked to a digital camera. Digital photo-
graphs were taken using a ×100 oil immersion objective lens
(Olympus, Japan). The magnification was calculated using an
objective micrometer. For quantitative analysis of dark neu-
rons, the physical dissector method was carried out [28, 29].
The first section of each pair was designated as the reference
and the second one was used for comparison. On each pair of
sections, at least ten microscopic fields were selected by
uniform systematic random sampling in the entorhinal cortex
(EC). Using unbiased frame and physical dissector counting
rule, the counting of dark neurons in each field was carried out
[28, 29].
Poly I:C Administration
Poly I:C was obtained from InvivoGen (San Diego, CA,
USA). Poly I:C was stored at −20 °C until use. It was prepared
for injection by resusupending in sterile saline, heating to
50 °C at a concentration of 2 mg/ml to ensure complete
solubility and then allowing cooling naturally at room tem-
perature. Six hours after the third and fourth KCl injections,
rats were treated with poly I:C (PIC/CSD group; n=8;
0.3 mg/kg per i.p. injection) to examine systemic and brain
inflammatory responses to its systemic administration.
Splenic Cytokine Assay
One week after the last KCl or Ringer injection, the spleens
were removed and their splenocytes were isolated. The resul-
tant cell suspension was washed by centrifuging at 600×g for
10 min at 4 °C and red blood cells lysed with red blood cell
lysis buffer (0.16 M NH4Cl, 10 mM KHCO3, and 0.13 mM
ethylenediaminetetraacetic acid; EDTA). Debris was re-
moved from the suspension via a 70 μm nylon mesh filter
and after washing, the cells were then suspended in RPMI
1,640 (containing 0.075 % sodium bicarbonate, 10 mM
HEPES buffer, 100 U/ml penicillin G, 100 μg/ml strepto-
m y c i n s u l f a t e , 1 . 5 mM L - g l u t am i n e , a n d 2 -
mercaptoethanol) +10 % heat-inactivated FBS. Cell num-
bers were counted using trypan blue exclusion method and
the percentage of cell viability was calculated. Cell suspen-
sions were added in triplicate to flat-bottom 96-well plates
at a volume of 200 μl/well, and plates were incubated at
37 °C and 5 % CO2. To stimulate the cells, 1 μg/ml phyto-
hemagglutinin (PHA; Sigma Aldrich, St. Louis, MO) was
added. Supernatants were collected after 48 h in culture and
stored frozen at −80 °C for cytokine analysis by ELISA.
Tumor necrosis factor alpha (TNF-α; Santa Cruz, Germa-
ny), interferon gamma (IFN-γ), interleukin-4 (IL-4),
transforming Growth Factor beta 1 (TGF-β1), and
granulocyte-macrophage colony-stimulating factor (GM-
CSF; Abcam, Cambridge, UK) were measured following
the manufacturer’s instructions. Cytokine concentrations
were quantified by using standard curves generated using
serial dilutions of recombinant proteins. The values were
measured with a microplate reader at 490 nm.
CNS Cytokine Assay
One week after the last KCl or Ringer injection, rats were
decapitated and the brains were removed. Before decapita-
tion, the animals were given a deep anesthesia with chloral
hydrate (350 mg/kg; Sigma Aldrich) and perfused
transcardially with 200 ml of saline followed by 600 ml of
1 % PFA solution. Rat brain was homogenized in ice-cold
buffer (8 ml of buffer per g of brain) consisting of 20 mM
Tris HCl (pH 7.4), 5 mM EDTA, 5 mM dithiothreitol,
0.2 mM phenylmethylsulfonyl fluoride, chymostatin
(1 μg/ml), pepstatin (1 μg /ml), and trypsin inhibitor
(1 μg/ml; all from Sigma) in phosphate-buffered saline
solution (pH 7.2) containing 0.5 % Triton X-100. Brain
homogenate was spun at 4 °C for 10 min at 1000×g. The
levels of IFN-γ, IL-4, TGF-β1, GM-CSF (all from Abcam,
Cambridge, UK) and TNF-α (Santa Cruz, Germany) were
determined in brain supernatant using sandwich-base
ELISA kit following the manufacturer’s instruction. All
tests were performed in triplicate for each rat.
Fig. 1 Recordings of negative direct currents (DC) after injection of KCl
(3 mol/l) in juvenile rat brain. A stainless steel, 23-gauge guide cannula
and two silver recording electrodes (2–3mm apart) were implanted above
the somatosensory neocortex and fixed with dental acrylic cement.
Cortical spreading depression (CSD) was recorded from the
somatosensory cortex of juvenile rats without (A) and with (B)
administration of poly I:C
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Lymphocyte Proliferation Assay
One week after the fourth KCl or Ringer application, the
splenocytes at a concentration of 2×105 cells/well (after red
blood cells clearance) were cultured with supplemented
RPMI-1,640 with 10 % FBS in 96-well flat-bottom culture
plates (Nunc, Denmark) in the presence of T cell mitogen
PHA (Sigma, USA) at a concentration of 1 μg/ml per well
at 37 °C in 5 % CO2. After 48 h of incubation, 10 μg/ml of
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
(Invitrogen, USA) was added to each well and incubated for
4 h at 37 °C in 5 % CO2. Following incubation, the superna-
tant from each well was aspirated carefully and formazan
crystals were solubilized by adding 100 μl dimethyl sulfoxide
into each well. The absorbance of each well was then deter-
mined at a wavelength of 540 nm, and the results expressed as
a stimulation index (SI). All tests were performed in triplicate
for each rat.
Immunohistochemistry
Animals were deeply anesthetized with 3.5 % chloral hydrate
and perfused transcardially with 200 ml of saline followed by
200 ml of 1 % PFA solution. The brains were extracted and
kept in 1 % PFA for at least 10 days at 4 °C and were then
processed for immunohistochemical studies. The serial
(8 μm) coronal sections were prepared. Three paraffin em-
bedded sections were selected by random systematic sampling
from each animal and rehydrated through a series of xylol and
alcohol and washed with phosphate-buffered saline (PBS)
three times and incubated in blockage solution (3 % H2O2/
methanol for 5 min). Then slides were heated in sodium citrate
buffer at 95 °C for 10 min. After cooling at room temperature
for 20 min, slides were washed with PBS three times and
incubated overnight at 4 °Cwith commercial rabbit polyclonal
anti-rat antibody (Abcam, Cambridge, UK) against
GABAAα, GABAAβ, and glutamic acid decarboxylase 65
(GAD65) overnight separately. Its concentration for HSP-70
was 1:300, GABAAαwas 1:100, for GABAAβwas 1: 50, and
for GAD65 was 1:200 in a solution containing 1–5 % NGS in
0.3 % Triton X-100 and 0.1 M PBS at pH of 7.4. The sections
were then rinsed three times in PBS (10 min each) and
incubated with goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody (Abcam, Cambridge, United
Kingdom) diluted at 1:400 in PBS with 0.3 % Triton X-100
and 5 % NGS at 22 °C for 1 h. After several washings with
PBS, the slides were incubated and developed in 3-3′-diami-
nobenzidine (DAB, Roche; 0.5 μl DAB and 1.5 μl peroxide
buffer) for 5–10 min. Sections were counterstained with he-
matoxylin. Control for the specificity of immunostaining was
performed by the omission of the primary antibody. Images
for analysis were acquired with a digital camera attached to a
microscope (BX51, Olympus, Japan).
Statistical Analysis
Data were expressed as mean±S.E.M. Statistical analysis was
carried out by using one-way analysis of variance (ANOVA)
followed by Tukey’s post hoc test. The criterion for statistical
significance was P<0.05.
Results
Application of KCl into the brain of juvenile rats caused
negative DC fluctuations, which were followed by positive
waves. The mean number of amplitude and duration of the
first neocortical CSD-like waves were 10.8±2.1 mV and
112±9 s and the velocity of propagation of these negative
DC shifts were 3±0.2 mm/min (n=8; Fig. 1(A)). The am-
plitude and duration as well as the speed of propagation of
CSD events that were repeatedly induced in the following
4 weeks of experiments were not significantly different
from the characteristic features of the first CSD waves.
However, the mean number of CSD induced by KCl injec-
tion was statistically increased during 4 weeks of experi-
ments. The number of CSD recorded during 60 min after
KCl injection was 1.4±0.2 in the first week, 1.8±0.3 in the
second week, 2.1±0.2 in the third week, and 2.5±0.3 in the
fourth week (P=0.036). Application of i.p. poly I:C did not
affect the amplitude, duration, and repetition rate of CSD-
like waves. The same pattern of negative DC deflections
was observed in PIC/CSD rats compared to CSD group (n=
8; Fig. 1(B)). KCl injection did not induce epileptiform
burst discharges in any of tested animals.
CNS Cytokine Assay
We investigated whether poly I:C treatment could influence
changes of cytokine patterns after induction of CSD in the
brain. The cytokine production was evaluated in brain super-
natant using sandwich-base ELISA assay. In the brain homog-
enates, no significant differences were observed in the level of
IL-4 in CSD (n=6; 58±6.3) and PIC/CSD (n=6; 60±5.2)
groups compared to sham rats (n=6; 52.4±9.9). However,
induction of repetitive CSD significantly increased IFN-γ
(188.8±18.3; P≤0.001), TNF-α (211.7±40.6; P≤0.001),
TGF-β1 (154.1±22; P≤0.001), and GM-CSF (67.6±19; P≤
0.05) production compared to sham group (IFN-γ, 86.5±
18.5; TNF-α, 70.7±16; TGF-β1, 61.7±16.07; and GM-
CSF, 48.2±6; Fig. 2a). Administration of poly I:C significant-
ly reduced the levels of TNF-α (109±13.4; P≤0.001) and
IFN-γ (143±21.1; P≤0.05) in the brain homogenates com-
pared to CSD group (Fig. 2a).
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Spleen Cytokine Assay
Cellular immune responses were evaluated by cytokine secre-
tion assay of the in vitro stimulated splenocytes in CSD, PIC/
CSD and sham groups. IFN-γ secretion is a marker of Th1
type cellular immune responses, while IL-4 is recognized as
Th2-biased response. In addition to these cytokines, we also
evaluated pro-inflammatory (TNF-α and GM-CSF) and anti-
inflammatory (TGF-β1) cytokine profiles. As shown in
Fig. 2b, production of IFN-γ (338.2±39.7), TNF-α (638.6±
43), and TGF-β1 (305.2±31.8) in splenocyte of CSD group
(n=6) was significantly higher than the levels of IFN-γ (58.4
±8.6), TNF-α (65.5±9.9), and TGF-β1 (83.6±22.4) in sham
rats (n=6; P<0.001; Fig. 2b). Furthermore, production of
splenic IL-4 (87.6±8.9) after CSD induction was significantly
higher than IL-4 values in sham groups (65±21.5, P≤0.05;
Fig. 2b). Administration of poly I:C (PIC/CSD group, n=6) in
the third and fourth weeks of the experiments significantly
reduced production of TNF-α (215±53, P≤0.001) and IL-4
(59±6.1, P≤0.05) compared to CSD group. PIC/CSD group
also showed a significant increase of IFN-γ (331.1±40,
P<0.001), TNF-α (215±53, P≤0.001), and TGF-β1 (264±
13, P<0.05) compared to sham rats. There were no significant
differences in splenic GM-CFS production among different
groups (CSD, 81.5±29.3; PIC/CSD, 80±11; sham, 64.5±
16.7; Fig. 2b).
Lymphocyte Proliferation Assay
To determine whether splenocyte proliferation response could
be affected by CSD and systemic administration of poly I:C,
lymphocytes from CSD and PIC/CSD rats were evaluated and
Fig. 2 Enzyme-linked
immunosorbent assay (ELISA) of
IFN-γ, IL-4, TNF-α, TGF-β1,
and GM-CSF in the brain (a) and
spleen (b) of sham animals, rats
affected by repetitive cortical
spreading depression (CSD) as
well as rats affected by CSD and
treated with poly I:C (PIC/CSD).
CSD was induced by application
of KCl on dura mater of juvenile
rats and ECoG was recorded by
implanted silver electrodes. a
Induction of CSD significantly
increased the production of
IFN-γ, TNF-α, TGF-β1, and
GM-CSF in the brain but did not
affect IL-4. Administration of
Poly I:C after CSD significantly
reduced the production of IFN-γ
and TNF-α compared to CSD
group. b Induction of CSD
significantly enhanced the
production of IFN-γ, TNF-α, IL-
4, and TGF-β1 in the spleen but
did not affect GM-CSF.
Administration of poly I:C after
CSD significantly reduced the
production of IL-4 and TNF-α
compared to CSD group. Data are
from four independent
experiments (mean±S.E.M.). *,
**, and ** indicate significant at
P≤0.05, 0.01, and P≤0.001,
respectively (one-way ANOVA
test)
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compared with sham-treated animals. As shown in Fig. 3,
induction of CSD significantly increased lymphocyte prolif-
eration compared to sham animals (P≤0.001). However, ad-
ministration of poly I:C did not change lymphocyte stimula-
tion index compared to CSD group (n=6 for each group;
Fig. 3).
Immunohistochemical Distribution of Hsp70, GAD65,
and GABAA
Hsp70 plays a crucial role in protecting neurons from cellular
stresses [30]. Our results showed a significant higher expres-
sion of Hsp70 immunoreactivity in rats treated with poly I:C
compared to CSD and sham groups (P≤0.001; Fig. 4). The
mean number of the reacted cells per square millimeter of
Hsp70 in EC was 0.008±0.002 in CSD, 0.012±0.002 in
sham, and 0.025±0.002 in PIC/CSD rats. There was no sig-
nificant difference in expression of Hsp70 between CSD and
sham groups (n=6 for each group; Fig. 4a, b).
It is suggested that the production of some cytokines, such
as TNF-α, during CSD may affect neuronal inhibitory tone in
the brain [12]. GAD, an enzyme that catalyzes the decarbox-
ylation of glutamate to GABA, exists in two isoforms encoded
by two different isoforms; GAD67 and GAD65. In CSD
animals, GAD65 displayed a significant higher immunoreac-
tivity in EC compared to sham rats (P≤0.001). Administration
of poly I:C markedly decreased the expression of the mean
number of GAD65 reacted neurons compared to CSD group
(P≤0.05; Fig. 4a, b). To clarify the changes in GABAA
receptors after CSD with and without treatment with poly
I:C, we analyzed the distribution of GABAAα and GABAAβ
in EC. The expression of both GABAAα and GABAAβ did
not change after induction of CSD compared to sham group.
However, treatment with poly I:C significantly enhanced the
expression of GABAAα and GABAAβ in EC compared to
CSD and sham animals (n=6 for each group; P≤0.001;
Fig. 4a, b).
Number of Dark Neurons
Dark neurons were identified by neuronal shrinkage, nuclear
pyknosis, and surrounding spongiosis [28, 29]. The mean
number of dark neurons in EC was significantly increased
after induction of CSD compared to sham rats (P≤0.001).
Treatment with poly I:C significantly decreased the number
of dark cells compared to CSD group (P≤0.001). The mean
number of dark neurons in PIC/CSD rats, however, was
higher than in sham group (n=8 for each group; P≤0.05;
Fig. 5a, b).
Discussion
The present study indicates the TLR3-mediated modulatory
effects on CSD-induced production of pro- and anti-
inflammatory cytokines in the brain and spleen as well as
the expression of Hsp70, GAD, GABAAα, and GABAAβ in
EC of juvenile rats. In addition, our data demonstrate the
protective role of TLR3 activation on neuronal injury induced
by repetitive CSD in EC. Our previous studies demonstrated
that changes of synaptic plasticity of EC is important for CSD
penetration to deeper brain structures and therefore ECmay be
a target of therapy to reduce the neurological deficits occurred
in CSD-related disorders [31, 32].
In agreement with our results, it has been shown that CSD
alters expression of different inflammatory pathways in the
brain. CSD induced persistent upregulation of TNF-α and IL-
1 mRNA whereas IL-2, IL-10, IL-12, and C4 complement
protein mRNAwere downregulated in rat brain after CSD [33,
34]. The upregulation of IL-1α, -1β, -2, -4, -6, and -10 as well
as IFN-γ and TNF-α at the protein level following spreading
depression in hippocampal organotypic cultures has been
reported [13]. CSD causes activation of caspase-1 which in
turn initiates inflammation by releasing high-mobility group
box 1 (HMGB1) and IL-1β from neurons and nuclear factor
κB (NF-κB) from astrocytes. HMGB1 behaves like a cytokine
and promotes inflammation. Activation of NF-κB after CSD
can also provide the sustained inflammatory mediator release
to the subarachnoid space [35]. Increases in extracellular K+
concentrations during CSD augments lipopolysaccharide-
elicited neurotoxicity in neuroglia mixed cultures via en-
hanced production of inflammatory factors, such as TNF-α
[36]. Free arachidonic acid also significantly increased during
initiation and propagation of CSD [37].
Fig. 3 Lymphocyte proliferation levels in the spleen of sham animals,
rats affected by repetitive cortical spreading depression (CSD) as well as
rats affected by CSD and treated with poly I:C (CSD/PIC). One week
after final CSD induction, spleens of individual rats were removed and
lymphocyte proliferation was evaluated. Induction of CSD significantly
increased the stimulation index compared to sham-treated rats.
Administration of poly I:C after induction of CSD did not change this
index. Data are from four independent experiments (mean±S.E.M.). ***
indicates significant at P≤0.001 (one-way ANOVA test)
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Our study for the first time revealed that, in addition to the
brain, CSD influences the systemic immune system. CSD
enhanced production of IFN-γ, TNF-α, TGF-β1, and IL-4
in the spleen and increased proliferation response of splenic
lymphocytes. To date, there has been little interest in exploring
the possibility of systemic immune responses to CSD. There
are, however, several studies demonstrating occurrence of
systemic immune responses in CSD-related neurological dis-
orders, i.e., stroke and migraine [38]. Alterations in function
of polymorphonuclear cells, monocytes, and natural killer
cells (phagocytosis/chemotaxis) were reported in migrainures
[39]. Lymphocytes of patients with migraine exhibited in-
creased dopamine D5-receptor expression [40], decreased β-
adrenergic receptor sensitivity [41], and decreased β-
Fig. 4 Immunohistochemistry
assay of Hsp70, GAD, GABAAα,
and GABAAβ in the entorhinal
cortex of sham animals, rats
affected by repetitive cortical
spreading depression (CSD) as
well as rats affected by CSD and
treated with poly I:C (CSD/PIC).
a Photomicrographs of
immunohistochemistry of Hsp70,
GAD, GABAAα, and GABAAβ
expression in the entorhinal
cortex in sham, CSD, and CSD/
PIC rats. b The bar graph shows
the quantitative results (mean±
SEM) of Hsp70, GAD65,
GABAAα, and GABAAβ
expression. Data are expressed as
number of Hsp70, GAD,
GABAAα and GABAAβ
expression per square millimeter.
Compared with sham animals,
there was a significant increase in
Hsp70, GABAAα and GABAAβ
expression in the entorhinal
cortex of CSD/PIC rats. The
expression of GAD65, however,
was significantly higher
compared to sham rats.
Administration of poly I:C
significantly reduced the
expression of GAD65 compared
to CSD group. Values represent
mean±SEM. * and ** indicate
significant at P≤0.05 and P≤
0.001, respectively (one-way
ANOVA test)
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endorphin levels [42]. Migraine patients showed higher serum
levels of TNF-α and IL-1β interictally [43]. A decrease in
plasma IL-4 and IL-6 levels and an increase in plasma GM-
CSF and IFN-γ values has been reported after a challenge test
in patients with migraine [44]. Lymphocytes from stroke
survivors showed more activity against antigens (such as
myelin basic protein) compared to the lymphocytes from
patients with multiple sclerosis [45]. Myelin-reactive T cells
were found in higher numbers among patients with cerebro-
vascular disease [46]. Further studies are needed to elucidate
whether CSD play a role on systemic immune responses of
these neurological disorders.
The up- or downregulation of the systemic immune re-
sponse has the ability to modulate brain dysfunctions [47].
Modulation of microglia/macrophages and lymphocytes infil-
tration in the brain has been suggested to play a role in
treatment of neurological disorders (such as multiple sclerosis,
Alzheimer’s disease, and amyotrophic lateral sclerosis) by
preventing neuronal damage, improving repair, and eliminat-
ing toxic proteins [48–50]. Systemic administration of poly
I:C, in our study, suppressed production of TNF-α and IFN-γ
in the brain as well as splenic TNF-α and IL-4 after marked
enhancement of these cytokines by CSD. Neuronal activities
trigger low-level pro-inflammatory signaling involving
TNF-α, resulting in an enhanced resilience of the brain to
withstand injury [12]. The activation of TNF receptor two on
inhibitory interneurons may reduce normal brain activity in
neurological diseases that are associated with blocking effect
on CSD [51]. Conversely, high-level TNF-α possesses the
brain’s intrinsic capacity to enhance neuronal injury and death
[12, 52, 53]. An increased IFN-γ from microglia after induc-
tion of CSD has been suggested as the first signal heralding a
cytokine-cascade-based modulation of brain ischemic injury
[13]. IL-4 plays a major role on activation and proliferation of
B-cell, modulation of macrophage functions, and differentia-
tion of T cell [54]. Anti-inflammatory effects of IL-4 on
activated microglia have been noted, including inhibition of
the expression of TNF-α and IFN-γ [55, 56].
Previous studies have shown that a limited number of CSD
failed to influence the expression of Hsp72 [57–59].
Fig. 5 The effects of repetitive cortical spreading depression (CSD) with
and without administration of poly I:C (CSD/PIC) on themean number of
dark neurons in the entorhinal cortex in juvenile rats after 4 weeks of
repetitive CSD induction. CSD was induced by application of KCl on
dura mater and ECoG was recorded by implanted silver electrodes. a
Light-microscopic appearance (×40 magnification) of transverse sections
of the rat brain in CSD, CSD/PIC, and sham groups stained with toluidine
blue, revealing an increase of dark neurons in the entorhinal cortex after
CSD induction and decrease after administration of poly I:C. b The mean
number of dark neurons in the entorhinal cortex of sham, CSD and CSD/
PIC rats. Number of dark neurons was compared between experimental
groups and analyzed by one-way ANOVA followed by Tukey’s multiple
comparison tests. Values represent mean±SEM. * and ** indicate
significant at P≤0.05 and P≤0.001, respectively
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Multifocal regions of increased Hsp70 expression were
observed in both ipsilateral and contralateral hemispheres
after induction of CSD by cerebral embolic events [60];
failed to prove whether increased expression of Hsp70
was due to CSD or ischemic insults. Indeed, precondition-
ing with brief ischemia can lower the threshold signal for the
induction of heat shock proteins [61]. Our results showed a
significant reduction of Hsp70 after 4 weeks of repetitive
CSD. Expression of this neuroprotective protein, however,
significantly increased after TLR3 activation by adminis-
tration of poly I:C. Due to Hsp70 chaperone role and/or to
its ability to protect brain against neurotoxic factors, inflam-
mation, and apoptosis, it has been suggested that Hsp70
may play a neuroprotective role in some neurological dis-
orders, such as multiple sclerosis, epilepsy, ischemic brain
injury, etc.[30]. It has been shown that TNF-α is involved in
modulating the failure of Hsp70-positive astrocytes to pro-
vide functional support to neuritic outgrowth in neuron-
astrocyte cultures [62]. Our previous studies demonstrated
occurrence of neuronal injury after repetitive CSD in juve-
nile rats [28, 29]. The present data indicate that administra-
tion of poly I:C significantly decreased the mean number of
dark neurons; an index of neuronal injury [63]. This may be
due to decreases in production of TNF-α [64] and IFN-γ
[65] and/or enhancement of Hsp70 expression [66] after
application of poly I:C.
Partial GABAA-mediated inhibition plays a role in main-
taining the late excitatory period following the depression
phase of CSD [67, 68] and contributes to CSD-linked epi-
leptiform activity [4, 69]. It has been shown that the expres-
sion of GAD65 was increased in response to an increased
neuronal activity induced by partial inhibition of GABAA
receptors [70] or neuronal injury induced by pilocarpine
[71]. In addition to increases of GAD65, our data revealed
a significant enhancement of GABAAα and GABAAβ ex-
pression in EC after administration of poly I:C. Adminis-
tration of TNF-α produced a rapid and persistent decrease
of inhibitory synaptic strength and a downregulation of
GABAA receptors [72]. IFN-γ stimulation of human mac-
rophage lineage cells increased gamma aminobutyric acid
transporter-2 expression and reduced extracellular GABA
levels [73]; conversely, activation of GABA receptors
inhibited IFN-γ production [74]. Triggering of CSD re-
quires activation of NMDA receptors [3] and the brain
releases glutamate during CSD propagation [75]. Neuronal
injury induced by exposure to NMDA, AMPA, or kainate
was attenuated by activation of GABAA receptors in mouse
cortical cell cultures [76]. Administration of poly I:C en-
hanced the expression of GABAAα and GABAAβ and
reduced the expression of GAD. It has been shown that
release of both GABAAα and GABAAβ downregulates
GAD activity in neuronal tissues [77], possibly via influ-
ence of GABA on the translation of GAD mRNA [78].
Activation of different TLR subtypes can initiate either
immunostimulatory or immunomodulatory responses in the
brain [79]. Although TLR stimulation increases the produc-
tion of the inflammatory molecules, such as TNF-α, and
exacerbates tissue damage, activation of these receptors prior
to neuronal injury protects the brain from damage [79]. Acti-
vation of TLR generates tumor-specific immune responses to
brain tumors, and modulation of these receptors suppresses
the damaging inflammatory responses to brain ischemia and
enhances the endogenous protection of neuronal injury [80,
81].Modulation of TLR9 significantly reduced ischemic dam-
age in a nonhuman primate model of stroke [82] and TLR2
[83] as well as TLR4 [84] plays a crucial role in cerebral
ischemic/reperfusion injury in different animal models and
that their activation leads to exacerbation of infarct volume
and mortality. Activation of TLR3, in our study, reduced the
mean number of CSD-induced dark neurons. Our previous
studies indicate that repetitive CSD in juvenile rats causes
neuronal damage and death in both cortical and subcortical
structures of the brain [28, 29]. The neuroprotective effects of
TLR3 by application of poly I:C has been shown in brain
in vivo and in vitro ischemia models. Reduction of pro-
inflammatory cytokine production and enhancement of anti-
inflammatory cytokine production from the injured astrocytes
have been suggested as the underlying neuroprotective mech-
anism of poly I:C in brain ischemia [25, 81, 85]. Poly I:C
improved neuronal survival in organotypic human brain slice
cultures [24] and reduced oxygen-glucose deprivation-medi-
ated cell death in mouse mixed cortical cultures [79]. It is
suggested that poly I:C decreases in cerebral ischemia/
reperfusion injury via TLR3 by preventing the interaction of
apoptosis antigen 1 and its associated protein with death
domain and reduction of microglial cell caspase-3 and -8
activities [86]. Activation of TLR3 increases synaptic trans-
mission in the spinal cord and plays a critical role in regulating
sensory neuronal excitability as well as central sensitization
[87].
Conclusion
In addition to the previous data indicating cytokine signaling
after CSD in the brain, our results demonstrate that CSD
modulates the adaptive immunity and systemic inflammatory
response. Furthermore, we have identified TLR3 as a critical
signaling molecule that can modulate CSD-induced neuroin-
flammation and neuronal injury. Targeting TLR3may provide
a novel strategy for developing new treatments for CSD-
related neurological disorders.
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